SeekingAlpha · Aug 9, 2026
Kirin Holdings Company, Limited 2026 Q2 - Results - Earnings Call Presentation
2026-08-09. The following slide deck was published by Kirin Holdings Company, Limited in conjunction with their 2026 Q2 earnings call.
KN
OTC · KNBWY
Kirin Holdings Company, Limited
Consumer Defensive · Beverages - Alcoholic
$19.59
Up+$0.52 (+2.73%)
Updated Aug 17, 2026, 12:35 AM
SID Score
5.0/10
Composite research score
Smart Money
53/100
Neutral
- Market cap
- 12.35B
- P/E ratio
- 34.91
- Dividend yield
- 2.49%
- 52-week range
- — – —
- Volume
- 1.5K
- Avg. volume
- 33.88K
Price performance
KNBWY price history
1M range · 0 trading sessions · Daily adjusted prices
KNBWY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest KNBWY news
The latest Smart Investors Daily articles mentioning KNBWY.
Stock researchCompany · Overview
KNBWY research
Overview
Company profile and research snapshot.
Company profile
KIRIN HLDGS CO LTD S/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · Feb 16, 2026
Kirin Holdings Company, Limited 2025 Q4 - Results - Earnings Call Presentation
2026-02-16. The following slide deck was published by Kirin Holdings Company, Limited in conjunction with their 2025 Q4 earnings call.
globenewswire.com · Dec 2, 2025
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) has been completed. Under Kura's collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, “Kyowa Kirin”), this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
